Auris Medical Provides Business Update and Reports Fourth Quarter and Full Year 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/5/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
Jefferies Cuts Price target on Auris Medical Holding (EARS) Following 4Q
March 15, 2016 8:30 AM EDTJefferies maintained a Buy rating on Auris Medical Holding AG (NASDAQ: EARS), and cut the price target to $8.00 (from $12.00), following the company's 4Q. Although management continues to see enrollment completion for TACTT2 this month, the topline results for both TACTT trials are... More
Auris Medical Holding (EARS) Reports Q4 Loss of CHF0.16/Share
March 14, 2016 6:36 AM EDTAuris Medical Holding (NASDAQ: EARS) reported Q4 EPS of (CHF0.16), versus (CHF0.17) reported last year.
"We achieved significant progress with our development programs in 2015, bringing us closer to the completion of the pivotal AM-101 tinnitus trials and advancing the late-stage AM-111 hearing loss program," commented Thomas Meyer, Auris Medical's founder, Chairman and Chief Executive Officer. "We look forward to the upcoming results of our Phase 3 AM-101 program, initiating the second of our Phase 3 AM-111 trials and attaining further progress towards our ultimate goal of providing effective and safe inner ear therapeutics for... More
